Laboratorios Farmaceuticos Rovi (ROVI) Resumen de Acciones
Laboratorios Farmacéuticos Rovi, S.A. fabrica, vende y comercializa productos farmacéuticos en España, la Unión Europea, los países de la OCDE y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 5/6 |
| Dividendos | 3/6 |
Recompensas
Análisis de riesgos
ROVI Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€51.25
FV
16.4% sobrevalorado descuento intrínseco4.00%
Revenue growth p.a.
157
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Competidores de Laboratorios Farmaceuticos Rovi, S.A.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €59.65 |
| Máximo en las últimas 52 semanas | €86.70 |
| Mínimo de 52 semanas | €51.65 |
| Beta | 0.22 |
| Cambio en 1 mes | 1.79% |
| Variación en 3 meses | -24.16% |
| Cambio de 1 año | 7.00% |
| Variación en 3 años | 35.63% |
| Variación en 5 años | 0.93% |
| Variación desde la OPV | 496.50% |
Noticias y actualizaciones recientes
Artículo de análisis • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...
Actualización de narrativa • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.Recent updates
Artículo de análisis • Jul 26
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Released Its Half-Year Earnings: Here's What Analysts Think
Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...Actualización de narrativa • Jun 18
ROVI: Contract Manufacturing Expansion And Dividend Capacity Will Support Future Share Returns
Analysts have trimmed their fair value estimate for Laboratorios Farmaceuticos Rovi stock from about €76.49 to roughly €75.38, citing a slightly less optimistic outlook on revenue growth, profit margins and future P/E multiples after recent downgrades from several firms. Analyst Commentary Recent commentary around Laboratorios Farmaceuticos Rovi focuses on how recent downgrades affect expectations for execution, valuation and growth, rather than on any single data point in isolation.Actualización de narrativa • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Artículo de análisis • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Actualización de narrativa • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.Actualización de narrativa • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.Actualización de narrativa • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.Actualización de narrativa • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.Actualización de narrativa • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.Actualización de narrativa • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.Artículo de análisis • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Artículo de análisis • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Artículo de análisis • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Artículo de análisis • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nueva narrativa • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Artículo de análisis • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Artículo de análisis • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Artículo de análisis • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...Artículo de análisis • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...Artículo de análisis • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Artículo de análisis • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Artículo de análisis • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...Artículo de análisis • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...Artículo de análisis • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Artículo de análisis • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...Artículo de análisis • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...Artículo de análisis • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...Rentabilidad de los accionistas
| ROVI | ES Pharmaceuticals | Mercado ES | |
|---|---|---|---|
| 7D | 9.0% | 7.3% | 1.8% |
| 1Y | 7.0% | 6.0% | 32.8% |
Rentabilidad vs. Industria: ROVI superó a la industria Spanish Pharmaceuticals, que obtuvo un rendimiento del 6% el año pasado.
Rentabilidad vs. Mercado: ROVI obtuvo unos resultados inferiores a los del mercado Spanish, que fueron del 32.8% el año pasado.
Volatilidad de los precios
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 3.2% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.6% |
| 10% least volatile stocks in ES Market | 0.7% |
Precio estable de las acciones: El precio de las acciones de ROVI ha sido volátil durante los últimos 3 meses en comparación con el mercado Spanish.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ROVI(5%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Spanish.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1946 | 2,470 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmacéuticos Rovi, S.A. fabrica, vende y comercializa productos farmacéuticos en España, la Unión Europea, los países de la OCDE y a escala internacional. La empresa ofrece productos de prescripción, como Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler y Volutsa. También suministra productos hospitalarios, como Iomeron e Iopamiro, Multihance e Y Prohance, Sonovue, Empowercta+, Empowermr y CT Express; cuidado de catéteres bajo la marca Fibrilin; y heparina sódica Rovi.
Resumen de fundamentos de Laboratorios Farmaceuticos Rovi, S.A.
| Estadísticas fundamentales de ROVI | |
|---|---|
| Capitalización bursátil | €3.05b |
| Beneficios(TTM) | €185.18m |
| Ingresos (TTM) | €773.05m |
16.5x
Ratio precio-beneficio (PE)3.9x
Ratio precio-ventas (PS)¿Está ROVI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ROVI | |
|---|---|
| Ingresos | €773.05m |
| Coste de los ingresos | €272.63m |
| Beneficio bruto | €500.42m |
| Otros gastos | €315.24m |
| Beneficios | €185.18m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 3.62 |
| Margen bruto | 64.73% |
| Margen de beneficio neto | 23.95% |
| Ratio deuda/patrimonio | 15.0% |
¿Cómo se ha desempeñado ROVI a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.6%
Rentabilidad actual por dividendo26%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/28 04:14 |
| Precio de las acciones al final del día | 2026/07/28 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Laboratorios Farmaceuticos Rovi, S.A. está cubierta por 13 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |